Established 2017
Mekonos enables industrial scale genome editing for therapeutics and therefore making gene therapies universally accessible. Mekonos is also developing a new approach for cell engineering using a proprietary silicon chip technology (KAREL) that delivers molecules into potentially, millions of individual cells.